Renaissance Technologies LLC has recently announced that it has increased stake in Humanigen Inc. (NASDAQ:HGEN) by 72.32%. After grabbing 1.49 million shares, the institutional investor is now in possession of 0.63 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 1.25% having worth around $0.22 million. Moreover, The Bank of New York Mellon Corp increased its share by 0.26 million to have a control over 0.88 million shares. And Virtu Financial BD LLC raised its holdings to 0.21 million shares by acquiring 0.3 million shares or 0.25% of the stake.
Humanigen Inc. (HGEN) concluded trading on 03/16/23 at a closing price of $0.16, with 1.37 million shares of worth about $0.22 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -26.37% during that period and on Thursday the price saw a loss of about -0.32%. Currently the company’s common shares owned by public are about 119.08M shares, out of which, 104.84M shares are available for trading.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 3 analysts are covering the HGEN stock and their offered price forecasts bring an average price target of $3.22. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $9.00 and could fall to a lowest price of $0.15. However, touching the estimated high of $9.00 would mean a gain of 98.22% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 9 times over the past 12 months. They bought 1,042,996 shares in 9 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and iShares Tr. – Micro Cap ETF are the top 3 mutual funds which are holding stakes in Humanigen Inc. Vanguard Extended Market Index Fu is currently holding 0.68 million shares of worth totaling $0.1 million. The company recently came buying 0.0 shares which brought its stake up to 0.57% of the company’s outstanding shares. iShares Tr. – Micro Cap ETF, after buying 0.2 million shares, have now control over 0.17% of the stake in the company. It holds 0.0 shares of worth $30563.0.
Humanigen Inc. (NASDAQ: HGEN) started trading at $0.1548, below -$0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 0.1596, or with a loss of -0.32%. Stock saw a price change of 4.36% in past 5 days and over the past one month there was a price change of -12.22%. Year-to-date (YTD), HGEN shares are showing a performance of 31.67% which decreased to -93.95% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.09 but also hit the highest price of $4.11 during that period. The average intraday trading volume for Humanigen Inc. shares is 3.72 million. The stock is currently trading 2.18% above its 20-day simple moving average (SMA20), while that difference is down -4.02% for SMA50 and it goes to -69.56% lower than SMA200.
Renaissance Technologies LLC acquired 1.49 million shares of Humanigen Inc. having value of about $0.22 million. Data submitted at the U.S SEC by Renaissance Technologies LLC revealed that the firm now holds 0.63 million shares in the company valued at close to $100171.36, or have control over 72.32% stake in the company. Humanigen Inc. (NASDAQ: HGEN) currently have 119.08M outstanding shares and institutions hold larger chunk of about 6.10% of that. Holding of mutual funds in the company is about 14.77% while other institutional holders and individual stake holders have control over 14.91% and 1.41% of the stake respectively.
The stock has a current market capitalization of $20.31M and its 3Y-monthly beta is at -0.84. It has posted earnings per share of -$1.52 in the same period. It has Quick Ratio of 0.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HGEN, volatility over the week remained 10.01% while standing at 11.11% over the month.
Analysts are in expectations that Humanigen Inc. (HGEN) stock would likely to be making an EPS of -$0.06 in the current quarter, while forecast for next quarter EPS is $0 and it is -$0.34 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.11 which is -$0.02 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.53 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -66.90% while it is estimated to increase by 66.00% in next year. EPS is likely to shrink at an annualized rate of 12.50% for next 5-years, compared to annual growth of 21.90% made by the stock over the past 5-years.
Analysts at 3 brokerage firms have issued recommendations for the Humanigen Inc. (HGEN)’s stock and average of those rates the stock at a “Hold” and assign it a score of 3.30. Out of those 3 Wall Street analysts, 0 recommended a “Buy” rating, while 2 were in favor recommending the stock as a “Hold” and 1 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on July 13, 2022 offering a Neutral rating for the stock and assigned a target price range of between $13 and $2 to it. On July 13, 2022, Cantor Fitzgerald Downgrade their recommendations, while on September 10, 2021, Jefferies Downgrade their ratings for the stock with a price target of $9. Stock get a Buy rating from H.C. Wainwright on September 09, 2021.
Leave a Reply